Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Immune Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Immune Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Immune Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Immune Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Immune Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Immune Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Immune Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Immune Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Immune Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Immune Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Immune Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immune Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Immune Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Immune Pharmaceuticals, Inc. Snapshot 5 Immune Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Immune Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Immune Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Immune Pharmaceuticals, Inc. - Pipeline Products Glance 14 Immune Pharmaceuticals, Inc. - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Immune Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Immune Pharmaceuticals, Inc. - Early Stage Pipeline Products 17 IND/CTA Filed Products/Combination Treatment Modalities 17 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Immune Pharmaceuticals, Inc. - Unknown Stage Pipeline Products 20 Unknown Products/Combination Treatment Modalities 20 Immune Pharmaceuticals, Inc. - Drug Profiles 21 (amitriptyline + ketamine) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 bertilimumab 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 crolibulin 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 EP-1013 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Anti Ferritin Gemcitabine Paclitaxel NanomAbs 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Ferritizumab 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Nanomab Targeting EGFR 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Nanomab Targeting HER2 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Nanomab Targeting HER3 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 (ketamine + butamben) 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Immune Pharmaceuticals, Inc. - Pipeline Analysis 34 Immune Pharmaceuticals, Inc. - Pipeline Products by Target 34 Immune Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 36 Immune Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 37 Immune Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 38 Immune Pharmaceuticals, Inc. - Recent Pipeline Updates 40 Immune Pharmaceuticals, Inc. - Dormant Projects 45 Immune Pharmaceuticals, Inc. - Discontinued Pipeline Products 46 Discontinued Pipeline Product Profiles 46 histamine dihydrochloride 46 verubulin 46 Immune Pharmaceuticals, Inc. - Locations And Subsidiaries 47 Head Office 47 Other Locations & Subsidiaries 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 49 Disclaimer 49
List of Tables Immune Pharmaceuticals, Inc., Key Information 5 Immune Pharmaceuticals, Inc., Key Facts 5 Immune Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Immune Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 Immune Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 Immune Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014 11 Immune Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 12 Immune Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 13 Immune Pharmaceuticals, Inc. - Phase III, 2014 14 Immune Pharmaceuticals, Inc. - Phase II, 2014 15 Immune Pharmaceuticals, Inc. - Phase I, 2014 16 Immune Pharmaceuticals, Inc. - IND/CTA Filed, 2014 17 Immune Pharmaceuticals, Inc. - Preclinical, 2014 18 Immune Pharmaceuticals, Inc. - Discovery, 2014 19 Immune Pharmaceuticals, Inc. - Unknown, 2014 20 Immune Pharmaceuticals, Inc. - Pipeline by Target, 2014 35 Immune Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 36 Immune Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 37 Immune Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 39 Immune Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 40 Immune Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 45 Immune Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 46 Immune Pharmaceuticals, Inc., Other Locations 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
